drug · small molecule
bitopertin
Phase 2updated 6mo agoby $IRON Disc Medicine, Inc.🔗 ChEMBL
Phase 2community read0 votes
Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 5 investigational indications.
targets
Sodium- and chloride-dependent glycine transporter 1
all catalysts(0)
nothing on the calendar yet
News(8)
- AstraZeneca, Calidi, Tempest make significant workforce cutsFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 18h ago
- Disc’s redemption, China’s rise, Veradermics’ validation, ESMO’s headlinersChina cracks down on some biotechnology ownership transfers—but will the new policy impact licensing deals?; Disc Medicine’s Phase 3 data sweep redeems rejected rare disease therapy, teeing up anot…biospace · 26d ago
- Disc’s once-spurned rare disease drug to get a second chance at approvalMonths after the FDA rejected its treatment for a rare light-sensitivity disease, the biotech claimed success in a Phase 3 trial and now plans to re-engage regulators.biopharma_dive · 28d ago
- Disc’s rebuffed rare disease drug sets up FDA redo after ‘clean’ Phase 3 sweepDisc Medicine’s bitopertin—rejected by the FDA in February—significantly reduced levels of a key disease biomarker and significantly increased the time patients with erythropoietic protoporphyria w…biospace · 29d ago
- Disc’s rebuffed rare blood disease drug sets up FDA re-do after ‘clean’ Phase 3 sweepDisc Medicine’s bitopertin—rejected by the FDA in February—significantly reduced levels of a key disease biomarker and significantly increased the time patients with erythropoietic protoporphyria w…biospace · 29d ago
- Disc spins past FDA rejection with ‘overwhelmingly positive’ phase 3 data for rare disease drugA phase 3 trial of Disc Medicine’s bitopertin has hit both co-primary endpoints and all secondary endpoints, positioning the biotech to refile for approval of the once-rejected rare disease drug ca…fiercebiotech · 29d ago
- Capricor, Replimune reviews signal FDA’s return to reliability but every application will stand aloneFollowing a tumultuous stretch under ex-Commissioner Marty Makary, current FDA leadership is working to restore reliability, integrity and transparency to the agency—but experts say that doesn’t ne…biospace · 2mo ago
- US ‘eroding’ lead in rare diseases a matter of national security: ReportA Congressional advisory panel recommends the U.S. government put supportive policies in place for rare disease drug development, such as a finalized platform designation from the FDA and the allow…biospace · 3mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that